Dasatinib 100 Mg Oral Tablet
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Osteopenia, Osteoporosis
Conditions
Osteopenia, Osteoporosis, Age-related Bone Loss
Trial Timeline
Sep 6, 2023 → Apr 30, 2026
NCT ID
NCT06018467About Dasatinib 100 Mg Oral Tablet
Dasatinib 100 Mg Oral Tablet is a phase 2 stage product being developed by Novo Nordisk for Osteopenia, Osteoporosis. The current trial status is active. This product is registered under clinical trial identifier NCT06018467. Target conditions include Osteopenia, Osteoporosis, Age-related Bone Loss.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06018467 | Phase 2 | Active |
Competing Products
18 competing products in Osteopenia, Osteoporosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Teriparatide + Zoledronic Acid | Eli Lilly | Approved | 85 |
| alendronate sodium | Merck | Approved | 85 |
| zoledronic acid | Novartis | Phase 3 | 77 |
| zoledronic acid vs pamidronate | Novartis | Approved | 85 |
| Zoledronic Acid + Placebo | Novartis | Phase 3 | 77 |
| BPS804 20mg/Kg + Placebo to 20mg/Kg BPS804 | Novartis | Phase 2 | 52 |
| Placebo + ibandronate [Bonviva/Boniva] | Roche | Approved | 85 |
| ibandronate [Bonviva/Boniva] + Placebo | Roche | Phase 3 | 77 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Placebo + AMG 167 | Amgen | Phase 1 | 32 |
| AMG 167 + Placebo | Amgen | Phase 1 | 32 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| Denosumab | Amgen | Phase 3 | 76 |
| Romosozumab + Placebo | Amgen | Phase 1 | 32 |
| RN564 | Pfizer | Phase 1 | 32 |
| risedronate + alendronate | Sanofi | Phase 1 | 32 |
| Menostar (Estradiol, BAY86-5435) + Raloxifene | Bayer | Phase 3 | 74 |
| tibolone + raloxifen | Organon | Approved | 80 |